Table 1.

Baseline characteristics of Oslo, Calgary [Cal], and Mount Sinai [MSH] cohorts.

	Oslo PSC-UC [n=19]	Oslo UC [n=18]	Cal PSC-UC [n=12]	Cal UC [n=12]	MSH UC [n=26]
Age at diagnosis* [years]	43 [19–77]	32 [16–61]	39 [24–59]	34 [8–66]	26 [14–57]
Gender [male]	15 [75]%	11 [55%]	7 [58%]	6 [50%]	15 [54%]
IBD duration* [years]	15 [0–50]	0	2.2 [0.2–23]	10.3 [0.6–51]	6.2 [0–44]
5-aminosalicylate use	16 [80%]	0 [0%]	4 [33%]	10 [83%]	24 [86%]
Biopsy preservation method	Snap-frozen	Snap-frozen	RNAlater	RNAlater	Snap-frozen
Endoscopic Mayo score ≤ 1	19 [100%]	9 [50%]	12 [100%]	12 [100%]	18 [69%]

PSC-UC, primary sclerosing cholangitis-ulcerative colitis; Cal, Calgary; MSH, Mount Sinai Hospital; IBD, inflammatory bowel disease.